
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
Relapsed NeuroblastomaMetastatic PheochromocytomaThis expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

Expanded Access for ACE-011
Myelodysplastic SyndromeThis is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.

Expanded Access for AG-221
Acute Myeloid LeukemiaThis is an expanded access program (EAP) for eligible participants designed to provide access to AG-221.

Expanded Access for CC-486
Acute Myelogenous Leukemia (AML)This is an expanded access program (EAP) for eligible participants designed to provide access to CC-486.

Expanded Access to Ensartinib for Participants With ALK+ NSCLC
Non-Small Cell Lung CancerALK Gene Rearrangement PositiveThis is an open-label, multicenter, intermediate-sized expanded access treatment protocol to the existing IND 111,695 for ensartinib (X-396). The treatment plan is designed to provide ensartinib to participants with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).

Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)...
Urinary Tract InfectionsChronic Urinary Tract Infection3 moreAn Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology. This is for individuals for whom antibiotic therapy has failed, but of consideration in all cases, taking into account antibiotic-induced adverse reactions and increasing antibiotic resistance.

Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are...
The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3...
Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) MutationsThe purpose of this study is to provide expanded access to gilteritinib (ASP2215) for patients with FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed or refractory acute myeloid leukemia (AML) or with FLT3-mutated AML in composite complete remission (CRc: [complete remission (CR), complete remission with incomplete hematologic recovery (CRi), complete remission with incomplete platelet recovery (CRp)]) with minimal residual disease (MRD) without access to comparable or alternative therapy.

Expanded Access to NanoDoce
Urogenital NeoplasmsNanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.

Expanded Access to Elezanumab
Acute Spinal Cord Injury (SCI)Acute Ischemic StrokeThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.